Aptose Biosciences is a science-driven biotechnology company advancing first-in-class therapeutics to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Aptose is developing personalized medicines for precision treatment of these diseases, based on a patient’s specific gene signature. The company is also creating proprietary companion diagnostic tools to identify predisposed sensitivities to targeted therapies for use in single-agent or combination regimens. In the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies.
Based on insights into the genetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel oncology therapies to restore innate apoptotic controls that are circumvented by various cancers. Aptose appears to be the only company to seize on the Kruppel-Like Factor 4 (KLF4) gene’s distinctive profile in patients with AML and MDS. Notable scientific publications report that KLF4 gene expression is suppressed in patients with AML and in other hematologic cancers and that this gene suppression may serve as a key leukemogenic trigger. The Company’s lead program, APTO-253, induces expression of the silenced KLF4 gene, providing a new therapeutic approach for the treatment of this disease.
Aptose’s leadership team comprises accomplished industry, financial and clinical research professionals who are dedicated to building a comprehensive anticancer drug pipeline and clinical development programs focused on targeted therapeutics.